Fig. 2.

Clinical course of case 1. A Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) are shown, in addition to the administration period of nanoparticle albumin-bound paclitaxel (nab-PTX) and topical dorzolamide. The numbers on the horizontal line show weeks since topical dorzolamide first started. Time points of each OCT images taken are indicated by arrows. B–D Optical coherence tomography (OCT) images before and after topical dorzolamide treatment. A 6-mm horizontal sectional OCT scan (A: DRI OCT Triton, Topcon, Tokyo, Japan; B and C: RTVue XR Avanti, Optovue, Fremont, CA). Upper images are of the right eye and lower images are of the left eye. B OCT image when dorzolamide treatment was started, 3 weeks after the first visit for blurred vision and 5 weeks after the last nab-PTX treatment. Cystoid macular edema (CME) is observed bilaterally. C Six weeks after topical dorzolamide treatment was started. While CME is almost resolved and the foveal depression is restored in the right eye, CME is still observed in the left eye. D Ten weeks after topical dorzolamide was started. Foveal depression is restored bilaterally, and few cystoid spaces are observed